Article Text

Download PDFPDF

159:oral Scaling up neurological interventions in East Africa: a health economic evaluation
  1. J Hubbers1,
  2. Seid Ali Gugssa2,
  3. Tiwonge Elisa Khonje Phiri3,
  4. Omar Mwalim Omar4,
  5. Ayalew Moges Beyene5,
  6. Kigocha Okeng’o6,
  7. Mieraf Taddesse Tolla7,
  8. M Tessema Memirie S8,
  9. Øystein Haaland9,
  10. Kjell Arne Johansson10
  1. 1Bergen Center for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen, Norway; Helse Fonna, Haugesund, Norway
  2. 2Addis Ababa University, College of Health Sciences, School of Medicine, Department of Neurology, Addis Ababa, Ethiopia
  3. 3Queen Elizabeth Central Hospital, Department of Neurology, Blantyre, Malawi
  4. 4Bergen Center for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen
  5. 5Addis Ababa university, Department of pediatrics, Addis Ababa, Ethiopia
  6. 6Muhimbili National Hospital, Dar es Salaam, Tanzania
  7. 7Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA
  8. 8Bergen Center for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen
  9. 9Bergen Center for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen, Norway
  10. 10Bergen Center for Ethics and Priority Setting (BCEPS), University of Bergen, Bergen, Norway

Abstract

Neurological disorders are currently among the top causes of disability adjusted life-years (DALYs) and deaths globally. A vast increase in disease burden is projected, particularly in low- and lower middle-income countries (LLMIC). Paradoxically, in LLMIC settings, neurological disorders are often neglected, underdiagnosed, receive insufficient funding, and limited research. To combat the growing burden of disease, increasing focus must be placed on management of neurological disorders. Cost-effectiveness analyses of epilepsy (acute- and long-term management), migraine (first-line treatment, prophylaxis), Parkinson’s disease (drug treatment, physical therapy), and dementia (diagnosis and follow up, drug treatment, caregivers interventions) were performed to inform policy makers in Ethiopia, Malawi, and Tanzania. Health system costs were collected through a top-down microcosting method. Costing and coverage data were collected with expertise of East African neurologists and medical experts. Efficacy estimates were gathered by estimating the mortality or disability reduction, based on meta-analyses or systematic reviews. The cost-effectiveness analyses, calculating the incremental cost-effectiveness ratio (ICER), were conducted with FairChoices: DCP Analytics Tool. The health benefits of the interventions were estimated in DALYs averted. Cost-effectiveness analyses identified the long-term management of epilepsy (ICER: 0.35), self-managed treatment of migraine (ICER: 45.93), and support for dementia caregivers (ICER: 0.0004) as the best-buy interventions. Parkinson’s disease and the other dementia interventions were not deemed cost-effective in resource-constrained settings, because of its high costs or limited individual benefits. However, these interventions can be significantly impactful for patient’s families, indicating the need for further exploration of the non-health benefits using alternate methodology. The current findings support that an impact in managing neurological conditions can be made by scaling-up the identified cost-effective interventions in resource-constrained settings. By including these considerations carefully, a revision of the essential health benefit package can initiate a prime step forward in pursuit of poverty reduction and health equity.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.